QT lengthening and life-threatening arrhythmias associated with fexofenadine

Lancet

Volumn 353, Issue 9157, 1999, Pages 980-

  Pinto, Y M ^a   Van Gelder, I C ^a   Heeringa, M ^a   Crijns, H J G M ^a  

^a Department of Cardiology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; MACROLIDE; TERFENADINE;

AGED; ALLERGIC RHINITIS; ARTICLE; CARDIOTOXICITY; CASE REPORT; DRUG METABOLISM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MALE; MORTALITY; PRIORITY JOURNAL; PRURITUS; QT INTERVAL; SYNCOPE;

EID: 0033586418     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)01009-0     Document Type: Article

References (5)

1. Markham A., Wagstaff A.J. Fexofenadine. Drugs. 55:1998;269-274.
2. Product Information: Allegra (R), fexofenadine. Hoechst Marion Rousell, Inc, Kansas City, MO, 1997.
3. Eooslet R.L. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol. 36:1996;233-252.
4. Simons F.E., Bergma N.J., Watson W.T., Simons K.J. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol. 98:1996;1062-1064.
5. Faber T.S., Zehender M., Just H. Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf. 11:1994;463-476.